Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis

Am J Cardiol. 2023 Jul 15:199:33-36. doi: 10.1016/j.amjcard.2023.04.037. Epub 2023 May 26.

Authors

Sherin M Menachery¹, Yiwei Hang², Laura Pritchard³, Andrew Poklepovic³, Wendy Bottinor⁴

Affiliations

¹ Departments of Internal Medicine Virginia Commonwealth University Health System, Richmond, Virginia. Electronic address: sherin.menachery@vcuhealth.org.
² Virginia Commonwealth University School of Medicine, Richmond, Virginia.
³ Hematology-Oncology Virginia Commonwealth University Health System, Richmond, Virginia.
⁴ Cardiology, Virginia Commonwealth University Health System, Richmond, Virginia.

PMID: 37245247
PMCID: PMC10330624 (available on 2024-07-15)
DOI: 10.1016/j.amjcard.2023.04.037

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Immune Checkpoint Inhibitors
Myocarditis* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological

Grants and funding